Table 2 Drug-drug Interaction Prevalence
From: Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy
Primary analysis | ||||||
Study ID | Protocol: Exclude | Protocol: Avoid | Protocol: Caution | Lexicomp® | Clinically Relevant | |
DDI At Study Enrollment | S0711 | 12.0% (10/83) | 6.0% (5/83) | 2.4% (2/83) | 55.4% (46/83) | 12.0% (10/83) |
S0528 | 11.9% (10/84) | 3.6% (3/84) | 6.0% (5/84) | 2.4% (2/84) | 2.4% (2/84) | |
DDI Added During Study | S0711 | 13.3% (11/83) | 6.0% (5/83) | 2.4% (2/83) | 20.5% (17/83) | 13.3% (11/83) |
S0528 | 3.6% (3/84) | 0.0% (0/84) | 0.0% (0/84) | 0.0% (0/84) | 0.0% (0/84) | |
Secondary analysis | ||||||
Study ID | Protocol: Exclude | Protocol: Avoid | Protocol: Caution | Lexicomp® | Clinically Relevant | |
DDI At Study Enrollment | S0711 | 22.9% (19/83) | 6.0% (5/83) | 2.4% (2/83) | 55.4% (46/83) | 22.9% (19/83) |
S0528 | 11.9% (10/84) | 3.6% (3/84) | 6.0% (5/84) | 2.4% (2/84) | 2.4% (2/84) | |
DDI Added During Study | S0711 | 15.7% (13/83) | 6.0% (5/83) | 2.4% (2/83) | 20.5% (17/83) | 15.7% (13/83) |
S0528 | 6.0% (5/84) | 0.0% (0/84) | 0.0% (0/84) | 0.0% (0/84) | 0.0% (0/84) | |